The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the company’s shares following the finalized acquisition by its competitor, BioNTech. This move permanently closes the stock market chapter for the Tübingen-based mRNA pioneer, with its equity officially set to be removed from listings this week.
A Strategic Takeover, Not a Merger
The path to this outcome was set in mid-2025 with a purchase offer valued at approximately $1.25 billion. Through this acquisition, BioNTech not only resolved protracted patent disputes but also secured ownership of its former rival’s intellectual property. The integration has been executed decisively: CureVac’s entire board of directors has resigned. A committee led by BioNTech, which includes CEO Ugur Sahin, now oversees the operations, underscoring that this is a full absorption into the parent company rather than a merger of equals.
Should investors sell immediately? Or is it worth buying CureVac?
Final Trading Data and Share Conversion
Trading for CureVac stock on the Nasdaq was halted on January 6, 2026, with the final share price frozen at around $4.66. The formal delisting will become effective on Friday, January 16. Holdings belonging to public shareholders have been converted into American Depositary Shares (ADS) of BioNTech in accordance with the takeover agreement. Consequently, investor attention now shifts entirely to the strategic direction of the Mainz-based parent firm.
The Legacy: Technology and Infrastructure
For former shareholders, CureVac’s future financial calendars and metrics are now irrelevant. The central question is how BioNTech will utilize the acquired assets. Key components include the modern production facility in Tübingen and the “RNA Printer” technology, which enables the automated manufacturing of mRNA-based therapeutics. The future value of this acquisition within the BioNTech portfolio will hinge on how efficiently these resources can accelerate the development pipeline in oncology and infectious disease treatments.
Ad
CureVac Stock: Buy or Sell?! New CureVac Analysis from January 13 delivers the answer:
The latest CureVac figures speak for themselves: Urgent action needed for CureVac investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 13.
CureVac: Buy or sell? Read more here...
